Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 1561

Sort by

Sort Order Select

Journal Articles

Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations

Blood (2024) 144 (21): 2169–2173.

https://doi.org/10.1182/blood.2024025409

Published: 2024

Journal Articles

Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine

Hartmut Döhner, Keith W. Pratz, Courtney D. DiNardo, Andrew H. Wei, Brian A. Jonas, Vinod A. Pullarkat, Michael J. Thirman, Christian Récher, Andre C. Schuh, Sunil Babu, Xiaotong Li, Grace Ku, Zihuan Liu, Yan Sun, Jalaja Potluri, Monique Dail, Brenda Chyla, Daniel A. Pollyea

Blood (2024) 144 (21): 2211–2222.

https://doi.org/10.1182/blood.2024024944

Published: 2024

Includes: Supplemental data

Journal Articles

Preclinical efficacy of CDK7 inhibitor-based combinations against myeloproliferative neoplasms transformed to AML

Blood blood.2024026388.

https://doi.org/10.1182/blood.2024026388

Published: 2024

Includes: Supplemental data

Journal Articles

Imetelstat: A new addition to the Therapeutic Landscape of Lower-Risk MDS

Yasmin Abaza, Amy E. DeZern

Blood blood.2024025702.

https://doi.org/10.1182/blood.2024025702

Published: 2024

Includes: Supplemental data

Journal Articles

Risk prediction for clonal cytopenia: multicenter real-world evidence

Blood (2024) 144 (19): 2033–2044.

https://doi.org/10.1182/blood.2024024756

Published: 2024

Includes: Supplemental data

Journal Articles

Epigenetic regulation of noncanonical menin targets modulates menin inhibitor response in acute myeloid leukemia

Xinyue Zhou, Lixia Zhang, Sajesan Aryal, Virginia Veasey, Amanda Tajik, Cecilia Restelli, Steven Moreira, Pengcheng Zhang, Yanfeng Zhang, Kristin J. Hope, Yang Zhou, Changde Cheng, Ravi Bhatia, Rui Lu

Blood (2024) 144 (19): 2018–2032.

https://doi.org/10.1182/blood.2023023644

Published: 2024

Includes: Supplemental data

Journal Articles

Perspectives on drug development in chronic myelomonocytic leukemia: changing the paradigm

Anthony M. Hunter, Mrinal M. Patnaik, Raphael Itzykson, Ruben Mesa, Chatchada Karanes, Yanxia Li, R. Angelo de Claro, Kelly J. Norsworthy, Marc Theoret, Elizabeth Pulte, Eric Padron

Blood (2024) 144 (19): 1987–1992.

https://doi.org/10.1182/blood.2024025648

Published: 2024

Journal Articles

Asciminib monotherapy as frontline treatment of chronic-phase chronic myeloid leukemia: results from the ASCEND study

Blood (2024) 144 (19): 1993–2001.

https://doi.org/10.1182/blood.2024024657

Published: 2024

Includes: Supplemental data

Journal Articles

Acute Promyelocytic Leukemia: Long-Term Outcomes from the HARMONY Project

Blood blood.2024026186.

https://doi.org/10.1182/blood.2024026186

Published: 2024

Includes: Supplemental data

Journal Articles

Refined ELN 2024 risk stratification improves survival prognostication following venetoclax-based therapy in AML

Curtis A. Lachowiez, Vishvaas I Ravikumar, Jad Othman, Jenny O'Nions, Daniel T Peters, Christine McMahon, Ronan Swords, Rachel Cook, Jennifer N. Saultz, Jeffrey W. Tyner, Richard James Dillon, Joshua F. Zeidner, Daniel A. Pollyea

Blood blood.2024026925.

https://doi.org/10.1182/blood.2024026925

Published: 2024

Includes: Supplemental data

Journal Articles

Childhood Langerhans cell histiocytosis hematological involvement: severity associated with BRAFV600E loads

Blood blood.2024025625.

https://doi.org/10.1182/blood.2024025625

Published: 2024

Includes: Supplemental data

Journal Articles

Long-term Outcomes of tyrosine kinase inhibitors in chronic myeloid leukemia

François Guilhot, Rüdiger Hehlmann

Blood blood.2024026311.

https://doi.org/10.1182/blood.2024026311

Published: 2024

Journal Articles

Leukemic myeloblasts with erythrophagocytosis

Huifei Liu

Blood (2024) 144 (18): 1974.

https://doi.org/10.1182/blood.2024026257

Published: 2024

Journal Articles

A predictive model for therapy failure in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy

Blood (2024) 144 (18): 1951–1961.

https://doi.org/10.1182/blood.2024024761

Published: 2024

Includes: Supplemental data

Journal Articles

Current myeloproliferative neoplasm scoring systems for clinical practice

Hélène Pasquer, Jean-Jacques Kiladjian, Lina Benajiba

Blood blood.2024025459.

https://doi.org/10.1182/blood.2024025459

Published: 2024

Journal Articles

Proposals for revised International Working Group–European LeukemiaNet criteria for anemia response in myelofibrosis

Blood (2024) 144 (17): 1813–1820.

https://doi.org/10.1182/blood.2024025802

Published: 2024

Journal Articles

Germ line ERG haploinsufficiency defines a new syndrome with cytopenia and hematological malignancy predisposition

Jiarna R. Zerella, Claire C. Homan, Peer Arts, Xuzhu Lin, Sam J. Spinelli, Parvathy Venugopal, Milena Babic, Peter J. Brautigan, Lynda Truong, Luis Arriola-Martinez, Sarah Moore, Rachel Hollins, Wendy T. Parker, Hung Nguyen, Karin S. Kassahn, Susan Branford, Simone Feurstein, Lise Larcher, Flore Sicre de Fontbrune, Serwet Demirdas, Sonja de Munnik, Hélène Antoine-Poirel, Benedicte Brichard, Sahar Mansour, Kristiana Gordon, Marcin W. Wlodarski, Ashwin Koppayi, Sara Dobbins, Pim G. N. J. Mutsaers, Kim E. Nichols, Ninad Oak, Desiree DeMille, Rong Mao, Ali Crawford, Julie McCarrier, Donald Basel, Josue Flores-Daboub, Michael W. Drazer, Kerry Phillips, Nicola K. Poplawski, Graeme M. Birdsey, Daniela Pirri, Pia Ostergaard, Annet Simons, Lucy A. Godley, David M. Ross, Devendra K. Hiwase, Jean Soulier, Anna L. Brown, Catherine L. Carmichael, Hamish S. Scott, Christopher N. Hahn

Blood (2024) 144 (17): 1765–1780.

https://doi.org/10.1182/blood.2024024607

Published: 2024

Includes: Supplemental data

Journal Articles

Identifying disease-modifying potential in myelofibrosis clinical trials

David M. Ross, Steven W. Lane, Claire N. Harrison

Blood (2024) 144 (16): 1679–1688.

https://doi.org/10.1182/blood.2024024220

Published: 2024

Journal Articles

Influence of TP53 gene mutations and their allelic status in myelodysplastic syndromes with isolated 5q deletion

Blood (2024) 144 (16): 1722–1731.

https://doi.org/10.1182/blood.2024023840

Published: 2024

Includes: Supplemental data

Journal Articles

Molecular taxonomy of myelodysplastic syndromes and its clinical implications

Elsa Bernard, Robert P. Hasserjian, Peter L. Greenberg, Juan E. Arango Ossa, Maria Creignou, Heinz Tuechler, Jesus Gutierrez-Abril, Dylan Domenico, Juan S. Medina-Martinez, Max Levine, Konstantinos Liosis, Noushin Farnoud, Maria Sirenko, Martin Jädersten, Ulrich Germing, Guillermo Sanz, Arjan A. van de Loosdrecht, Yasuhito Nannya, Olivier Kosmider, Matilde Y. Follo, Felicitas Thol, Lurdes Zamora, Ronald F. Pinheiro, Andrea Pellagatti, Harold K. Elias, Detlef Haase, Christina Ganster, Lionel Ades, Magnus Tobiasson, Laura Palomo, Matteo Giovanni Della Porta, Pierre Fenaux, Monika Belickova, Michael R. Savona, Virginia M. Klimek, Fabio P. S. Santos, Jacqueline Boultwood, Ioannis Kotsianidis, Valeria Santini, Francesc Solé, Uwe Platzbecker, Michael Heuser, Peter Valent, Carlo Finelli, Maria Teresa Voso, Lee-Yung Shih, Michaela Fontenay, Joop H. Jansen, José Cervera, Norbert Gattermann, Benjamin L. Ebert, Rafael Bejar, Luca Malcovati, Seishi Ogawa, Mario Cazzola, Eva Hellström-Lindberg, Elli Papaemmanuil

Blood (2024) 144 (15): 1617–1632.

https://doi.org/10.1182/blood.2023023727

Published: 2024

Includes: Supplemental data

NARROW

Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations

Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine

Preclinical efficacy of CDK7 inhibitor-based combinations against myeloproliferative neoplasms transformed to AML

Imetelstat: A new addition to the Therapeutic Landscape of Lower-Risk MDS

Risk prediction for clonal cytopenia: multicenter real-world evidence

Epigenetic regulation of noncanonical menin targets modulates menin inhibitor response in acute myeloid leukemia

Perspectives on drug development in chronic myelomonocytic leukemia: changing the paradigm

Asciminib monotherapy as frontline treatment of chronic-phase chronic myeloid leukemia: results from the ASCEND study

Acute Promyelocytic Leukemia: Long-Term Outcomes from the HARMONY Project

Refined ELN 2024 risk stratification improves survival prognostication following venetoclax-based therapy in AML

Childhood Langerhans cell histiocytosis hematological involvement: severity associated with BRAFV600E loads

Long-term Outcomes of tyrosine kinase inhibitors in chronic myeloid leukemia

Leukemic myeloblasts with erythrophagocytosis

A predictive model for therapy failure in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy

Current myeloproliferative neoplasm scoring systems for clinical practice

Proposals for revised International Working Group–European LeukemiaNet criteria for anemia response in myelofibrosis

Germ line ERG haploinsufficiency defines a new syndrome with cytopenia and hematological malignancy predisposition

Identifying disease-modifying potential in myelofibrosis clinical trials

Influence of TP53 gene mutations and their allelic status in myelodysplastic syndromes with isolated 5q deletion

Molecular taxonomy of myelodysplastic syndromes and its clinical implications

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only